<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34860639</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Britanin relieves ferroptosis-mediated myocardial ischaemia/reperfusion damage by upregulating GPX4 through activation of AMPK/GSK3β/Nrf2 signalling.</ArticleTitle>
        <Pagination>
          <StartPage>38</StartPage>
          <EndPage>45</EndPage>
          <MedlinePgn>38-45</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2021.2007269</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Ferroptosis was described as an important contributor to the myocardial ischaemia/reperfusion (MIR) injury, and britanin (Bri) was reported to exert antitumor and anti-inflammatory activities.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our study explores the effect and mechanism of Bri on MIR damage.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The rat model of MIR was established by ligation of the left anterior descending coronary artery. Male Sprague-Dawley (SD) rats were divided into three groups: sham group (<i>n</i> = 6), MIR group (<i>n</i> = 6) and MIR + Bri group (<i>n</i> = 6; 50 mg/kg). Rats were intragastrically pre-treated with Bri or normal saline once daily for 3 days. To further verify the role and mechanism of Bri, H9C2 cells were subjected to hypoxia plus reoxygenation (H/R) to induce the <i>in vitro</i> model of MIR.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with MIR rats, Bri significantly decreased infarct area (22.50% vs. 38.67%), myocardial apoptosis (23.00% vs. 41.5%), creatine phosphokinase (0.57 U/mL vs. 0.76 U/mL), and lactate dehydrogenase levels (3.18 U/mL vs. 5.17 U/mL), concomitant with alleviation of ferroptosis. Mechanistically, Bri treatment induced the activation of the adenosine monophosphate activated protein kinase (AMPK)/glycogen synthase kinase 3β (GSK3β)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway <i>in vivo</i>. In addition, the AMPK/GSK3β/Nrf2 pathway participated in the regulation of glutathione peroxidase 4 (GPX4) expression, and silencing of Nrf2 attenuated the effect of Bri on H/R-induced cell injury.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Bri protected against ferroptosis-mediated MIR damage by upregulating GPX4 through activation of the AMPK/GSK3β/Nrf2 signalling, suggesting that Bri might become a novel therapeutic agent for MIR.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Haoyang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Manyu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Yangcheng</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Ren</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-3991-5366</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007783">Lactones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495637">Nfe2l2 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C575454">britannin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="C523860">glutathione peroxidase 4, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C000605508">Gsk3b protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007783" MajorTopicYN="N">Lactones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012717" MajorTopicYN="N">Sesquiterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Myocardial infarction</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">hypoxia-reoxygenation injury</Keyword>
        <Keyword MajorTopicYN="N">iron</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>17</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34860639</ArticleId>
        <ArticleId IdType="pmc">PMC8648013</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2021.2007269</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Barančík M, Grešová L, Barteková M, Dovinová I.. 
2016. Nrf2 as a key player of redox regulation in cardiovascular diseases. Physiol Res. 65 Suppl 1:S1–S10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27643930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi HJ, Chen ML, Yang XC, Lin XM, Sun H, Zhao WS, Qi D, Dong JL, Cai J.. 
2017. Progress in therapies for myocardial ischemia reperfusion injury. Curr Drug Targets. 18(15):1712–1721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27033199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding X, Jian T, Li J, Lv H, Tong B, Li J, Meng X, Ren B, Chen J.. 
2020. Chicoric acid ameliorates nonalcoholic fatty liver disease via the AMPK/Nrf2/NFκB signaling pathway and restores gut microbiota in high-fat-diet-fed mice. Oxid Med Cell Longev. 2020:9734560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7657699</ArticleId>
            <ArticleId IdType="pubmed">33204402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodson M, Castro-Portuguez R, Zhang DD.. 
2019. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 23:101107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6859567</ArticleId>
            <ArticleId IdType="pubmed">30692038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H, Qiang Z, Chai D, Peng J, Xia Y, Hu R, Jiang H.. 
2020. Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. Aging. 12(13):12943–12959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7377827</ArticleId>
            <ArticleId IdType="pubmed">32601262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan J, Guan Y, Mu F, Guo C, Zhang E, Yin Y, Wei G, Zhu Y, Cui J, Cao J, et al. . 
2017. Protective effect of butin against ischemia/reperfusion-induced myocardial injury in diabetic mice: involvement of the AMPK/GSK-3β/Nrf2 signaling pathway. Sci Rep. 7:41491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5269748</ArticleId>
            <ArticleId IdType="pubmed">28128361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang X, Wang H, Han D, Xie E, Yang X, Wei J, Gu S, Gao F, Zhu N, Yin X, et al. . 
2019. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 116(7):2672–2680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6377499</ArticleId>
            <ArticleId IdType="pubmed">30692261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fei B, Liu Z, Xie L, Lv L, Zhu W, Liu J, Dai Y, She W.. 
2020. Panax notoginseng saponins protect auditory cells against cisplatin‑induced ototoxicity by inducing the AKT/Nrf2 signaling‑mediated redox pathway . Mol Med Rep. 22(4):3533–3540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32945421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghaderi S, Alidadiani N, Dilaver N, Heidari HR, Parvizi R, Rahbarghazi R, Soleimani-Rad J, Baradaran B.. 
2017. Role of glycogen synthase kinase following myocardial infarction and ischemia-reperfusion. Apoptosis. 22(7):887–897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28421373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu C, Li T, Jiang S, Yang Z, Lv J, Yi W, Yang Y, Fang M.. 
2018. AMP-activated protein kinase sparks the fire of cardioprotection against myocardial ischemia and cardiac ageing. Ageing Res Rev. 47:168–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30110651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalogeris T, Baines CP, Krenz M, Korthuis RJ.. 
2016. Ischemia/reperfusion. Compr Physiol. 7(1):113–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5648017</ArticleId>
            <ArticleId IdType="pubmed">28135002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SG, Lee E, Park NY, Park HH, Jeong KT, Kim KJ, Lee YJ, Jin M, Lee E.. 
2016. Britanin attenuates ovalbumin-induced airway inflammation in a murine asthma model. Arch Pharm Res. 39(7):1006–1012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27342608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi M, Suhara T, Baba Y, Kawasaki NK, Higa JK, Matsui T.. 
2018. Pathological roles of iron in cardiovascular disease. Curr Drug Targets. 19(9):1068–1076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6469984</ArticleId>
            <ArticleId IdType="pubmed">29874997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Zandkarimi F, Zhang Y, Meena JK, Kim J, Zhuang L, Tyagi S, Ma L, Westbrook TF, Steinberg GR, et al. . 
2020. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol. 22(2):225–234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7008777</ArticleId>
            <ArticleId IdType="pubmed">32029897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Du G, Yang L, Pang L, Zhan Y.. 
2020. The antitumor effects of britanin on hepatocellular carcinoma cells and its real-time evaluation by in vivo bioluminescence imaging. Anticancer Agents Med Chem. 20(9):1147–1156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32106805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Zhong L, Wang F, Zhu H.. 
2017. Dissecting the role of AMP-activated protein kinase in human diseases. Acta Pharm Sin B. 7(3):249–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5430814</ArticleId>
            <ArticleId IdType="pubmed">28540163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K, Zhou Y, Chen Y, Zhou L, Liang J.. 
2020. A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-kappaB activation. Cancer Chemother Pharmacol. 85(4):699–709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32185482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lillo-Moya J, Rojas-Sole C, Munoz-Salamanca D, Panieri E, Saso L, Rodrigo R.. 
2021. Targeting ferroptosis against ischemia/reperfusion cardiac injury. Antioxidants. 10(5):667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8145541</ArticleId>
            <ArticleId IdType="pubmed">33922912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv H, Liu Q, Wen Z, Feng H, Deng X, Ci X.. 
2017. Xanthohumol ameliorates lipopolysaccharide (LPS)-induced acute lung injury via induction of AMPK/GSK3β-Nrf2 signal axis. Redox Biol. 12:311–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5345976</ArticleId>
            <ArticleId IdType="pubmed">28285192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GBD Mortality and Causes of Death Collaborators . 2016. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388(10053):1459–1544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5388903</ArticleId>
            <ArticleId IdType="pubmed">27733281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura T, Naguro I, Ichijo H.. 
2019. Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases. Biochim Biophys Acta Gen Subj. 1863(9):1398–1409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31229492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park TJ, Park JH, Lee GS, Lee JY, Shin JH, Kim MW, Kim YS, Kim JY, Oh KJ, Han BS, et al. . 
2019. Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes. Cell Death Dis. 10(11):835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6828761</ArticleId>
            <ArticleId IdType="pubmed">31685805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi K, Liu X, Du G, Cai X, Zhan Y.. 
2020. In vivo antitumour activity of britanin against gastric cancer through nuclear factor-κB-mediated immune response. J Pharm Pharmacol. 72(4):607–618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31943207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascon S, Hatzios SK, Kagan VE, et al. . 
2017. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 171(2):273–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D.. 
2016. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 63(1):173–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4688087</ArticleId>
            <ArticleId IdType="pubmed">26403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vomund S, Schafer A, Parnham MJ, Brune B, von Knethen A.. 
2017. Nrf2, the master regulator of anti-oxidative responses. Int J Mol Sci. 18(12):2772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5751370</ArticleId>
            <ArticleId IdType="pubmed">29261130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang GW, Qin JJ, Cheng XR, Shen YH, Shan L, Jin HZ, Zhang WD.. 
2014. Inula sesquiterpenoids: structural diversity, cytotoxicity and anti-tumor activity. Expert Opin Investig Drugs. 23(3):317–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24387187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu G, Zhu L, Yuan X, Chen H, Xiong R, Zhang S, Cheng H, Shen Y, An H, Li T, et al. . 
2017. Britanin ameliorates cerebral ischemia-reperfusion injury by inducing the Nrf2 protective pathway. Antioxid Redox Signal. 27(11):754–768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28186440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu MY, Yiang GT, Liao WT, Tsai AP, Cheng YL, Cheng PW, Li CY, Li CJ.. 
2018. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 46(4):1650–1667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29694958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Li Y, Zhang S, Zhou X.. 
2021. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 11(7):3052–3059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7847684</ArticleId>
            <ArticleId IdType="pubmed">33537073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Liu C, Li Z, Gai C, Ding D, Chen W, Hao F, Li W.. 
2020. Regulation of GSK3β/Nrf2 signaling pathway modulated erastin-induced ferroptosis in breast cancer. Mol Cell Biochem. 473(1–2):217–228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32642794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X, Guo Y, Du G, Liu H, Wang L, Chen D.. 
2020. Bioluminescence imaging-based assessment of the anti-triple-negative breast cancer and NF-Kappa B pathway inhibition activity of britanin. Front Pharmacol. 11:575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7215071</ArticleId>
            <ArticleId IdType="pubmed">32431613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Q, Zeng Y, Nie X, Guo Y, Zhan Y.. 
2020. Britanin exhibits potential inhibitory activity on human prostate cancer cell lines through PI3K/Akt/NF-κB signaling pathways. Planta Med. 86(18):1401–1410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32781474</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
